Encorafenib: all 58 studies that test it
Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingNCT07318389Early Phase 1
- Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.RecruitingNCT06640166Phase 2
- Combination Therapy for BRAF-V600E Metastatic CRCmRecruitingNCT06411600Phase 2
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaRecruitingNCT06194929Phase 1/2
- Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal CancerRecruitingNCT06102902Phase 1
- Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyRecruitingNCT05985954Phase 1
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum CancerRecruitingNCT05706779Phase 2
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingNCT05203172Phase 4
- Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesRecruitingNCT05026983Phase 2
- Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATERecruitingNCT04720768Phase 1/2
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingNCT04511013Phase 2
- Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2
- Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid TumorsCompletedNCT05003622Phase 1Results posted
- A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingNCT04607421Phase 3Results posted
- Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)TerminatedNCT04585815Phase 1/2Results posted
- Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E MutationTerminatedNCT04390243Phase 2Results posted
- Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementTerminatedNCT04221438Phase 2Results posted
- Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGGTerminatedNCT03973918Phase 2Results posted
- An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerCompletedNCT03915951Phase 2Results posted
- An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain MetastasisTerminatedNCT03911869Phase 2Results posted
- Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the BrainCompletedNCT03898908Phase 2Results posted
- Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid TumorsCompletedNCT03864042Phase 1Results posted
- A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant CancersCompletedNCT03843775Phase 1/2Results posted
- Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerCompletedNCT03693170Phase 2Results posted
- Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerCompletedNCT02928224Phase 3Results posted
- LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results posted
- LGX818 for Patients With BRAFV600 Mutated TumorsTerminatedNCT01981187Phase 2Results posted
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaCompletedNCT01909453Phase 3Results posted
- BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 MutationCompletedNCT01894672Phase 2Results posted
- LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF MelanomaTerminatedNCT01820364Phase 2Results posted
- A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaCompletedNCT01436656Phase 1Results posted
- Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + BinimetinibWithdrawnNCT07092410Phase 4
- Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRCActive, not recruitingNCT06578559Phase 2
- A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2
- ZN-c3 in Adult Participants With Metastatic Colorectal CancerTerminatedNCT05743036Phase 1
- Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon CancerActive, not recruitingNCT05710406Phase 2/3
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Active, not recruitingNCT05270044Phase 3
- A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingNCT05217446Phase 2
- Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Phase 2
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaActive, not recruitingNCT04657991Phase 3
- ENCOrafenib With Binimetinib in bRAF NSCLCActive, not recruitingNCT04526782Phase 2
- Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCLActive, not recruitingNCT04324112Phase 2
- Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal CancerTerminatedNCT04044430Phase 1
- Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04017650Phase 1/2
- Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant MelanomaTerminatedNCT03878719Phase 1
- Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF MutationsActive, not recruitingNCT03839342Phase 2
- Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaActive, not recruitingNCT03543969Early Phase 1
- Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV MelanomaActive, not recruitingNCT02910700Phase 2
- Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902042Phase 1/2
- BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)CompletedNCT02834364Phase 2
- CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)Status unknownNCT02675946Phase 1
- Sequential Combo Immuno and Target Therapy (SECOMBIT) StudyCompletedNCT02631447Phase 2
- Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway MutationsCompletedNCT02278133Phase 1/2
- Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 MutationsWithdrawnNCT02263898Phase 2
- Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLCWithdrawnNCT02109653Phase 2